# Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

> **NCT00615264** · PHASE3 · COMPLETED · sponsor: **Andromeda Biotech Ltd.** · enrollment: 457 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** DiaPep277
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00615264
- **Lead sponsor:** Andromeda Biotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2011-09
- **Final completion:** 2012-01
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615264, "Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00615264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*